In this issue of the HCV Advocate’s Mid-Month edition we present the following:
The Liver Conference 2015 – Part 2 – by Alan Franciscus
- I extracted some information from an excellent presentation from Dr. Norah Terrault’s Hepatitis Debrief. The articles include ‘Real World’ results of sofosbuvir plus ledipasvir that included information about people who were treated for 12 weeks but who were qualified for a shorter treatment duration of eight weeks.
There were also a couple of important studies about treating acute hepatitis C among people who inject drugs. Lastly, I wrote about various studies of drugs in development that are under review by the Food and Drug Administration (FDA)—Zepatier (elbasvir/grazoprevir) and sofosbuvir/velpatasvir. Both of the combinations are expected to be approved by the FDA in 2016.
Disability Insurance – A Survival Guide - by Jacques Chambers
- a must read for anyone who has long-term disability insurance offered by employers. This article describes how disability insurance works and the difference between this type of insurance and Social Security Disability Insurance.
HCV Advocate Monthly Pipeline Update – by Alan Franciscus –
I have updated our drug pipeline to include the latest information about the drugs in development to treat hepatitis C. I will also be updating the drug pipeline on a monthly basis so look for the pipeline in every Mid-Month edition of the HCV Advocate newsletter.
! In this month’s column we are asking for our website audience to consider a donation to the HCV Advocate/HCSP, A Project of the Tides Center. Help us continue our mission to support and educate the hepatitis C community.
Additionally, we are recommending HEP: www.hepmag.com
–an excellent website that educates and supports the viral hepatitis community.
Join us next month for more news about hepatitis C from the Liver Conference 2015 and our annual overview of the top news of 2015.
The staff of the HCV Advocate wish you and yours the best of the holiday season and a happy and healthy 2016.